Drug Type Bispecific antibody |
Synonyms Bispecific (Generate) |
Target |
Action inhibitors |
Mechanism IL-23 inhibitors(Interleukin-23 inhibitors), TL1A inhibitors(Tumor necrosis factor superfamily member 15 inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedDiscovery |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Colitis, Ulcerative | Discovery | United States | 01 Feb 2025 |






